Blake Borgeson - 07 Dec 2021 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Sale	$29,672	-1,500	-0.02%	$19.78	7,677,966	07 Dec 2021	Direct	F1, F2
transaction	RXRX	Class A Common Stock	Sale	$157,451	-7,725	-0.1%	$20.38	7,670,241	07 Dec 2021	Direct	F1, F3
transaction	RXRX	Class A Common Stock	Sale	$8,411	-400	-0.01%	$21.03	7,669,841	07 Dec 2021	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
F2	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.98 to $19.97 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $19.98 to $20.97 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F4	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.99 to $21.05 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.